Efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient advanced pancreatic adenocarcinoma: an AGEO European Cohort

Julien Taïeb,Lina Sayah,Kathrin Heinrich,Volker Kunzmann,Alice Boileve,Geert Cirkel,Sara Lonardi,Benoist Chibaudel,Anthony Turpin,Tamar Beller,Vincent Hautefeuille,Caterina Vivaldi,Thibault Mazard,Lucile Bauguion,Monica Niger,Gerald W. Prager,Clelia Coutzac, C. Benedikt Westphalen, Edouard Auclin,Lorenzo Pilla

European Journal of Cancer（2023）

Cited 7|Views36

No score

Abstract

•Largest series of metastatic MSI/dMMR PDAC patients treated by ICIs.•ORR and DCR were observed in 48.4% and 67.7% of the patients.•Median PFS was 26.7 months and median OS was not reached.•No significant difference was found between the different anti-PD(L)1 drugs.

Translated text

Key words

immune checkpoint inhibitors,pancreatic adenocarcinoma,repair-deficient

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined